Sukumar Nagendran, President and Head of R&D at Taysha Gene Therapies, sold TSHA on Jul 10, 2026
Data as of Oct 27
▼ SELL$1.2M200,000 shares at $6.24Sukumar Nagendran President and Head of R&DTSHA Taysha Gene Therapies, Inc.
- Traded
- Jul 10, 2026
- Disclosed
- Jul 10, 2026
- Filed
- The same day
Form 4s are due within two business days.
Official filing (SEC Form 4) ↗
The price around the disclosure
TSHA since disclosure
−33.0%
after the sale
Similar stocks (XLV) since disclosure
+11.4%
XLV — its sector index fund
Change in closing price from Jul 10, 2026 (the first trading day on or after disclosure) to Oct 27, 2026. Dividends excluded. Not a return anyone earned.
Our take
None of our tested rules fired on this trade.